{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:28:46Z","timestamp":1790749726207,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA2018SV-2311"],"award-info":[{"award-number":["RIA2018SV-2311"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA2018SV-2311"],"award-info":[{"award-number":["RIA2018SV-2311"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["733273"],"award-info":[{"award-number":["733273"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["733273"],"award-info":[{"award-number":["733273"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["733273"],"award-info":[{"award-number":["733273"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["733273"],"award-info":[{"award-number":["733273"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["NNF14CC0001"],"award-info":[{"award-number":["NNF14CC0001"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["NNF14CC0001"],"award-info":[{"award-number":["NNF14CC0001"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["NNF14CC0001"],"award-info":[{"award-number":["NNF14CC0001"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","award":["OPP1108403"],"award-info":[{"award-number":["OPP1108403"]}],"id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The <jats:italic>Plasmodium falciparum<\/jats:italic> Pfs230 and Pfs48\/45 proteins are leading candidates for a malaria transmission-blocking vaccine (TBV). Previously, we showed that a Pfs230\u2013Pfs48\/45 fusion protein elicits higher levels of functional antibodies than the individual antigens, but low yields hampered progression to clinical evaluation. Here we identified a modified construct (ProC6C) with a circumsporozoite protein (CSP) repeat-linker sequence that enhances expression. A scalable and reproducible process in the <jats:italic>Lactococcus lactis<\/jats:italic> expression system was developed and ProC6C was successfully transferred for manufacturing under current Good Manufacturing Practices (cGMP). In addition, a panel of analytical assays for release and stability were developed. Intact mass spectrometry analysis and multiangle light scattering showed that the protein contained correct disulfide bonds and was monomeric. Immunogenicity studies in mice showed that the ProC6C adsorbed to Alhydrogel<jats:sup>\u00ae<\/jats:sup>, with or without Matrix-M<jats:sup>TM<\/jats:sup>, elicited functional antibodies that reduced transmission to mosquitoes and sporozoite invasion of human hepatocytes. Altogether, our data support manufacture and clinical evaluation of ProC6C as a multistage malaria-vaccine candidate.<\/jats:p>","DOI":"10.1038\/s41541-021-00383-8","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T13:24:52Z","timestamp":1634045092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Preclinical development of a Pfs230-Pfs48\/45 chimeric malaria transmission-blocking vaccine"],"prefix":"10.1038","volume":"6","author":[{"given":"Susheel K.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Plieskatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishwanath K.","family":"Chourasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin L\u00f6vgren","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0287-4575","authenticated-orcid":false,"given":"Jenny M.","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate C.","family":"van Daalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Teelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marga","family":"van de Vegte-Bolmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert-Jan","family":"van Gemert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0686-370X","authenticated-orcid":false,"given":"Matthijs M.","family":"Jore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4412-1392","authenticated-orcid":false,"given":"Michael","family":"Theisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"383_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0196-3","volume":"5","author":"PE Duffy","year":"2020","unstructured":"Duffy, P. E. & Patrick Gorres, J. Malaria vaccines since 2000: progress, priorities, products. NPJ Vaccines 5, 48 (2020).","journal-title":"NPJ Vaccines"},{"key":"383_CR2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/imr.12828","volume":"293","author":"RM de Jong","year":"2020","unstructured":"de Jong, R. M. et al. Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites. Immunol. Rev. 293, 190\u2013215 (2020).","journal-title":"Immunol. Rev."},{"key":"383_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-3024.1987.tb00511.x","volume":"9","author":"N Kumar","year":"1987","unstructured":"Kumar, N. Target antigens of malaria transmission blocking immunity exist as a stable membrane bound complex. Parasite Immunol. 9, 321\u2013335 (1987).","journal-title":"Parasite Immunol."},{"key":"383_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S0031182015001341","volume":"143","author":"WJ Stone","year":"2016","unstructured":"Stone, W. J. et al. Naturally acquired immunity to sexual stage P. falciparum parasites. Parasitology 143, 187\u2013198 (2016).","journal-title":"Parasitology"},{"key":"383_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2989-2","volume":"18","author":"SM Lee","year":"2019","unstructured":"Lee, S. M. et al. The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate. Malar. J. 18, 356 (2019).","journal-title":"Malar. J."},{"key":"383_CR6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1128\/CVI.05104-11","volume":"18","author":"M Tachibana","year":"2011","unstructured":"Tachibana, M. et al. N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity. Clin. Vaccine Immunol. 18, 1343\u20131350 (2011).","journal-title":"Clin. Vaccine Immunol."},{"key":"383_CR7","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.vaccine.2019.02.021","volume":"37","author":"M Tachibana","year":"2019","unstructured":"Tachibana, M. et al. Identification of domains within Pfs230 that elicit transmission blocking antibody responses. Vaccine 37, 1799\u20131806 (2019).","journal-title":"Vaccine"},{"key":"383_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02646-2","volume":"9","author":"WJR Stone","year":"2018","unstructured":"Stone, W. J. R. et al. Unravelling the immune signature of Plasmodium falciparum transmission-reducing immunity. Nat. Commun. 9, 558 (2018).","journal-title":"Nat. Commun."},{"key":"383_CR9","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1084\/jem.162.5.1460","volume":"162","author":"AN Vermeulen","year":"1985","unstructured":"Vermeulen, A. N. et al. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J. Exp. Med. 162, 1460\u20131476 (1985).","journal-title":"J. Exp. Med."},{"key":"383_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-3024.1990.tb00990.x","volume":"12","author":"R Carter","year":"1990","unstructured":"Carter, R., Graves, P. M., Keister, D. B. & Quakyi, I. A. Properties of epitopes of Pfs 48\/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasite Immunol. 12, 587\u2013603 (1990).","journal-title":"Parasite Immunol."},{"key":"383_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1084\/jem.158.3.976","volume":"158","author":"J Rener","year":"1983","unstructured":"Rener, J., Graves, P. M., Carter, R., Williams, J. L. & Burkot, T. R. Target antigens of transmission-blocking immunity on gametes of plasmodium falciparum. J. Exp. Med. 158, 976\u2013981 (1983).","journal-title":"J. Exp. Med."},{"key":"383_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1017\/S0031182000062065","volume":"98","author":"T Ponnudurai","year":"1989","unstructured":"Ponnudurai, T. et al. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology 98, 165\u2013173 (1989).","journal-title":"Parasitology"},{"key":"383_CR13","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3389\/fimmu.2019.01256","volume":"10","author":"SK Singh","year":"2019","unstructured":"Singh, S. K. et al. Pfs230 and Pfs48\/45 fusion proteins elicit strong transmission-blocking antibody responses against Plasmodium falciparum. Front. Immunol. 10, 1256 (2019).","journal-title":"Front. Immunol."},{"key":"383_CR14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","volume":"65","author":"X Chen","year":"2013","unstructured":"Chen, X., Zaro, J. L. & Shen, W. C. Fusion protein linkers: property, design and functionality. Adv. Drug Deliv. Rev. 65, 1357\u20131369 (2013).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"383_CR15","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1021\/cr400525m","volume":"114","author":"R van der Lee","year":"2014","unstructured":"van der Lee, R. et al. Classification of intrinsically disordered regions and proteins. Chem. Rev. 114, 6589\u20136631 (2014).","journal-title":"Chem. Rev."},{"key":"383_CR16","doi-asserted-by":"publisher","first-page":"e0161607","DOI":"10.1371\/journal.pone.0161607","volume":"11","author":"J Zhao","year":"2016","unstructured":"Zhao, J., Bhanot, P., Hu, J. & Wang, Q. A comprehensive analysis of Plasmodium circumsporozoite protein binding to hepatocytes. PLoS ONE 11, e0161607 (2016).","journal-title":"PLoS ONE"},{"key":"383_CR17","doi-asserted-by":"publisher","first-page":"26951","DOI":"10.1074\/jbc.M109.013706","volume":"284","author":"ML Plassmeyer","year":"2009","unstructured":"Plassmeyer, M. L. et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J. Biol. Chem. 284, 26951\u201326963 (2009).","journal-title":"J. Biol. Chem."},{"key":"383_CR18","doi-asserted-by":"publisher","first-page":"E10438","DOI":"10.1073\/pnas.1715812114","volume":"114","author":"D Oyen","year":"2017","unstructured":"Oyen, D. et al. Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. Proc. Natl Acad. Sci. USA 114, E10438\u2013E10445 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"383_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm.4513","volume":"24","author":"J Tan","year":"2018","unstructured":"Tan, J. et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat. Med. 24, 401\u2013407 (2018).","journal-title":"Nat. Med."},{"key":"383_CR20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408\u2013416 (2018).","journal-title":"Nat. Med."},{"key":"383_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0972-0","volume":"14","author":"W Roeffen","year":"2015","unstructured":"Roeffen, W. et al. Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants. Malar. J. 14, 443 (2015).","journal-title":"Malar. J."},{"key":"383_CR22","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1016\/j.vaccine.2014.03.020","volume":"32","author":"M Theisen","year":"2014","unstructured":"Theisen, M. et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine 32, 2623\u20132630 (2014).","journal-title":"Vaccine"},{"key":"383_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijpara.2016.12.001","volume":"47","author":"J Jin","year":"2017","unstructured":"Jin, J. et al. Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal \u2018C-tag\u2019. Int. J. Parasitol. 47, 435\u2013446 (2017).","journal-title":"Int. J. Parasitol."},{"key":"383_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12934-017-0710-0","volume":"16","author":"SK Singh","year":"2017","unstructured":"Singh, S. K. et al. Construct design, production, and characterization of Plasmodium falciparum 48\/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine. Microb. Cell Fact. 16, 97 (2017).","journal-title":"Microb. Cell Fact."},{"key":"383_CR25","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.vaccine.2013.01.039","volume":"31","author":"SE Magnusson","year":"2013","unstructured":"Magnusson, S. E. et al. Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 31, 1725\u20131733 (2013).","journal-title":"Vaccine"},{"key":"383_CR26","doi-asserted-by":"publisher","first-page":"606266","DOI":"10.3389\/fimmu.2020.606266","volume":"11","author":"SK Singh","year":"2021","unstructured":"Singh, S. K. et al. A Reproducible and scalable process for manufacturing a Pfs48\/45 based Plasmodium falciparum transmission-blocking vaccine. Front. Immunol. 11, 606266 (2021).","journal-title":"Front. Immunol."},{"key":"383_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1074\/jbc.RA119.011268","volume":"295","author":"SK Singh","year":"2020","unstructured":"Singh, S. K. et al. The Plasmodium falciparum circumsporozoite protein produced in Lactococcus lactis is pure and stable. J. Biol. Chem. 295, 403\u2013414 (2020).","journal-title":"J. Biol. Chem."},{"key":"383_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/infdis\/jiw617","volume":"215","author":"IH Kana","year":"2017","unstructured":"Kana, I. H. et al. Naturally acquired antibodies target the Glutamate-Rich protein on intact merozoites and predict protection against Febrile malaria. J. Infect. Dis. 215, 623\u2013630 (2017).","journal-title":"J. Infect. Dis."},{"key":"383_CR29","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1016\/j.vaccine.2016.07.041","volume":"34","author":"SB Sirima","year":"2016","unstructured":"Sirima, S. B. et al. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. Vaccine 34, 4536\u20134542 (2016).","journal-title":"Vaccine"},{"key":"383_CR30","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.1016\/j.vaccine.2010.07.085","volume":"28","author":"B Mordmuller","year":"2010","unstructured":"Mordmuller, B. et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. Vaccine 28, 6698\u20136703 (2010).","journal-title":"Vaccine"},{"key":"383_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12934-018-0902-2","volume":"17","author":"SK Singh","year":"2018","unstructured":"Singh, S. K. et al. Lactococcus lactis provides an efficient platform for production of disulfide-rich recombinant proteins from Plasmodium falciparum. Microb. Cell Fact. 17, 55 (2018).","journal-title":"Microb. Cell Fact."},{"key":"383_CR32","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/j.vaccine.2015.02.040","volume":"33","author":"SK Singh","year":"2015","unstructured":"Singh, S. K. et al. A Plasmodium falciparum 48\/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies. Vaccine 33, 1981\u20131986 (2015).","journal-title":"Vaccine"},{"key":"383_CR33","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1016\/j.vaccine.2011.02.022","volume":"29","author":"S Lousada-Dietrich","year":"2011","unstructured":"Lousada-Dietrich, S. et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2\u2014a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 29, 3284\u20133292 (2011).","journal-title":"Vaccine"},{"key":"383_CR34","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/nm.3409","volume":"19","author":"SG Reed","year":"2013","unstructured":"Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597\u20131608 (2013).","journal-title":"Nat. Med."},{"key":"383_CR35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1586\/14760584.2013.814822","volume":"12","author":"KL Bengtsson","year":"2013","unstructured":"Bengtsson, K. L., Karlsson, K. H., Magnusson, S. E., Reimer, J. M. & Stertman, L. Matrix-M adjuvant: enhancing immune responses by \u2018setting the stage\u2019 for the antigen. Expert Rev. Vaccines 12, 821\u2013823 (2013).","journal-title":"Expert Rev. Vaccines"},{"key":"383_CR36","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.vaccine.2016.02.033","volume":"34","author":"KL Bengtsson","year":"2016","unstructured":"Bengtsson, K. L. et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine 34, 1927\u20131935 (2016).","journal-title":"Vaccine"},{"key":"383_CR37","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.vaccine.2013.12.030","volume":"32","author":"SE Magnusson","year":"2014","unstructured":"Magnusson, S. E. et al. Matrix-M adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice. Vaccine 32, 800\u2013808 (2014).","journal-title":"Vaccine"},{"key":"383_CR38","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1056\/NEJMc1803554","volume":"378","author":"V Shinde","year":"2018","unstructured":"Shinde, V. et al. Improved titers against influenza drift variants with a nanoparticle vaccine. N. Engl. J. Med. 378, 2346\u20132348 (2018).","journal-title":"N. Engl. J. Med."},{"key":"383_CR39","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","volume":"397","author":"MS Datoo","year":"2021","unstructured":"Datoo, M. S. et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet 397, 1809\u20131818 (2021).","journal-title":"Lancet"},{"key":"383_CR40","doi-asserted-by":"publisher","first-page":"e41451","DOI":"10.1371\/journal.pone.0041451","volume":"7","author":"JM Reimer","year":"2012","unstructured":"Reimer, J. M. et al. Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS ONE 7, e41451 (2012).","journal-title":"PLoS ONE"},{"key":"383_CR41","doi-asserted-by":"publisher","first-page":"e35213","DOI":"10.7554\/eLife.35213","volume":"7","author":"E Sherrard-Smith","year":"2018","unstructured":"Sherrard-Smith, E. et al. Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density. eLife 7, e35213 (2018).","journal-title":"eLife"},{"key":"383_CR42","first-page":"195","volume":"47","author":"H Holo","year":"1995","unstructured":"Holo, H. & Nes, I. F. Transformation of Lactococcus by electroporation. Methods Mol. Biol. 47, 195\u2013199 (1995).","journal-title":"Methods Mol. Biol."},{"key":"383_CR43","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ijpara.2012.09.002","volume":"42","author":"TS Churcher","year":"2012","unstructured":"Churcher, T. S. et al. Measuring the blockade of malaria transmission\u2013an analysis of the Standard Membrane Feeding Assay. Int J. Parasitol. 42, 1037\u20131044 (2012).","journal-title":"Int J. Parasitol."},{"key":"383_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.tree.2008.10.008","volume":"24","author":"BM Bolker","year":"2009","unstructured":"Bolker, B. M. et al. Generalized linear mixed models: a practical guide for ecology and evolution. Trends Ecol. Evol. 24, 127\u2013135 (2009).","journal-title":"Trends Ecol. Evol."},{"key":"383_CR45","doi-asserted-by":"publisher","first-page":"e00920","DOI":"10.1128\/IAI.00920-17","volume":"86","author":"MC Behet","year":"2018","unstructured":"Behet, M. C. et al. The complement system contributes to functional antibody-mediated responses induced by immunization with Plasmodium falciparum malaria sporozoites. Infect. Immun. 86, e00920\u201317 (2018).","journal-title":"Infect. Immun."},{"key":"383_CR46","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1084\/jem.157.6.1947","volume":"157","author":"F Zavala","year":"1983","unstructured":"Zavala, F., Cochrane, A. H., Nardin, E. H., Nussenzweig, R. S. & Nussenzweig, V. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J. Exp. Med. 157, 1947\u20131957 (1983).","journal-title":"J. Exp. Med."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00383-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00383-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00383-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T23:20:18Z","timestamp":1670023218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00383-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["383"],"URL":"https:\/\/doi.org\/10.1038\/s41541-021-00383-8","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"4 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}